Lode Gold Resources Inc. (TSXV: LOD) (OTCQB: SBMIF) (‘Lode Gold ‘ or the ‘Company’) is pleased to announce its wholly-owned subsidiary, (‘1475039 B.C. Ltd.’ or ‘Gold Orogen’) has entered into a binding Definitive Agreement (DA) on October 21, 2024 to acquire Great Republic Mining (‘GRM’, ‘Great Republic’ or CSE: GRM), pursuant to which the GRM and the Company’s subsidiary propose to complete a Reverse Take Over (RTO) transaction pursuant to which GRM will acquire all of the issued and outstanding shares of the Company’s subsidiary. It will be a tax efficient spin out: shareholders of Lode Gold will receive shares of Gold Orogen.

Transaction details, terms, and condition of the deal remain the same as in the Letter of Intent previously announced and can be read on its August 27th, 2024 news release.

The new company, Gold Orogen will have assets in two highly prospective areas in Canada: Yukon and Atlantic Canada. It will be a focused exploration pure play company. It will launch with funding of over $3 million dollars, with a plan to raise an additional $1.5 million. Work programs being executed or planned include: VTEM, SQUIDT, Soil Analysis, Geological Mapping, Trenching and Drilling in the next 12 months.

Wendy T. Chan, CEO of Lode Gold states, ‘We are very glad to have achieved yet another milestone, thanks to the hard work of our team. As promised in our business plan, we have now finalized definite spin out plans. It will be a tax efficient plan of arrangement. We will create two pure play companies to unlock value for shareholders. We have also initiated work programs in Yukon and New Brunswick, post raising over $4 million in the last two financings.’

About Lode Gold

Lode Gold (TSXV: LOD) is an exploration and development company with projects in highly prospective and safe mining jurisdictions in Canada and the United States.

Its Golden Culvert and WIN Projects in Yukon, covering 99.5 km2 across a 27-km strike length, are situated in a district-scale, high-grade-gold-mineralized trend within the southern portion of the Tombstone Gold Belt. Gold deposits and occurrences within the Belt include Fort Knox, Pogo, Brewery Creek and Dublin Gulch, and Snowline Gold. A NI 43-101 technical report entitled ‘Technical Report on the WIN-Golden Culvert Property for Lode Gold’ with an effective date of May 15, 2024, summarizing the work to date on these properties is available on the Company’s profile on SEDAR+ (www.sedarplus.ca) and on the Company’s website (www.lode-gold.com).

In New Brunswick, Lode Gold has created one of the largest land packages with a 42km strike within 420km2. Its McIntyre Brook Project, New Brunswick, covering 111 km2 and a 17-km strike length in the emerging Appalachian/Iapetus Gold Belt, is surrounded by Puma Exploration’s Williams Brook Project (5.55 g/t Au over 50m)1 and is hosted by orogenic rocks of similar age and structure as New Found Gold’s Queensway Project. The Fancamp’s Riley Brook is a 309 km2 package covering a 25 km strike of Wapske formation with its numerous felsic units. Previous exploration efforts have focused on just VMS-style mineralization hosted in the felsic intrusions, and mostly focused on the base metals – the Company is the first to focus on and assay for gold. This transaction will close upon Exchange’s acceptance.

The Company is also advancing its Fremont Gold development project in the historic Mother Lode Gold Belt of California where 50,000,000 oz of gold has been produced. Fremont, located 500km north of Equinox Gold’s Castle Mountain and Mesquite mines, has a Preliminary Economic Assessment(‘ PEA’) with an after-tax NPV (5%) of USD $217M, a 21% IRR, 11-year LOM, averaging 118,000 Oz per annum at USD $1,750 gold. A sensitivity to the March 31, 2023 PEA at USD $2,000/oz gold gives an after-tax NPV (5%) of USD $370M and a 31% IRR over an 11-year LOM. The project hosts an NI 43-101 resource of 1.16 MOz at 1.90 g/t Au within 19.0 MT Indicated and 2.02 MOz at 2.22 g/t Au within 28.3 MT Inferred. The MRE evaluates only 1.4 km of the 4 km strike length of the Fremont property which features five gold-mineralized zones. Significantly, three step-out holes at depth hit the mineralized structure, typical of orogenic deposits that often occur at depth. Fremont is located on 3,351 acres of 100% owned private land in Mariposa, the original Gold Rush County, and is 1.5 hours from Fresno, California. The property has year-round road access and is close to airports and rail.

Please refer to the Fremont Gold project NI 43-101 PEA technical report dated March 31, 2023, which is available on the Company’s profile on SEDAR+ (www.sedarplus.ca) and on the Company’s website (www.lode-gold.com). The PEA technical report has been reviewed and approved by independent ‘Qualified Persons’ Eugene Puritch, P.Eng., FEC, CET, and Andrew Bradfield, P.Eng. both of P&E, and Travis Manning, P.E. of KCA.

QUALIFIED PERSON STATEMENT

The scientific and technical information contained in this press release has been reviewed and approved by Jonathan Victor Hill, Director, BSc (Hons) (Economic Geology – UCT), FAusIMM, and who is a ‘qualified person’ as defined by NI-43-101.

ON BEHALF OF THE COMPANY

Wendy T. Chan, CEO & Director

Cautionary Note Related to this News Release and Figures

This news release contains information about adjacent properties on which the Company has no right to explore or mine. Readers are cautioned that mineral deposits on adjacent properties are not indicative of mineral deposits on the Company’s properties.

Cautionary Statement Regarding Forward-Looking Information

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes ‘forward-looking statements’ and ‘forward-looking information’ within the meaning of Canadian securities legislation. All statements included in this news release, other than statements of historical fact, are forward-looking statements including, without limitation, statements with respect to the completion of the transaction and the timing thereof, the expected benefits of the transaction to shareholders of the Company, the structure, terms and conditions of the transaction and the execution of a definitive agreement, the timing of submission to the CSE and TSXV, Gold Orogen raising an additional $1,500,000 and the anticipated use of proceeds. Forward-Looking statements include predictions, projections and forecasts and are often, but not always, identified by the use of words such as ‘anticipate’, ‘believe’, ‘plan’, ‘estimate’, ‘expect’, ‘potential’, ‘target’, ‘budget’ and ‘intend’ and statements that an event or result ‘may’, ‘will’, ‘should’, ‘could’ or ‘might’ occur or be achieved and other similar expressions and includes the negatives thereof.

Forward-Looking statements are based on a number of assumptions and estimates that, while considered reasonable by management based on the business and markets in which the Company operates, are inherently subject to significant operational, economic, and competitive uncertainties, risks and contingencies. These include assumptions regarding, among other things: that the Company and GRM will be able to negotiate the definitive agreement on the terms and within the time frame expected, that the Company and GRM will be able to make submissions to the CSE and TSXV within the time frame expected, that the Company and GRM will be able to obtain shareholder approval for the transaction, that the Company and GRM will be able to obtain necessary third party and regulatory approvals required for the transaction, if completed, that the transaction will provide the expected benefits to the Company and its shareholders.

There can be no assurance that forward-looking statements will prove to be accurate and actual results, and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include adverse market conditions, general economic, market or business risks, unanticipated costs, the failure of the Company and GRM to negotiate the definitive agreement on the terms and conditions and within the timeframe expected, the failure of the Company and GRM to make submissions to the CSE and TSXV within the timeframe expected, the failure of the Company and GRM to obtain shareholder approval for the transaction, the failure of the Company and GRM to obtain all necessary approvals for the transaction, and r other risks detailed from time to time in the filings made by the Company with securities regulators, including those described under the heading ‘Risks and Uncertainties’ in the Company’s most recently filed MD&A. The Company does not undertake to update or revise any forward-looking statements, except in accordance with applicable law.

1 See Puma Exploration Inc.’s news release dated September 15, 2021.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227250

Key Assay Highlights:

Total Samples Analyzed: 388 rock samples. Titanium Dioxide (TiO2): 49 samples returned assay values over 4.0% TiO2, with a maximum value of 11.1%. Vanadium Pentoxide (V2O5): 36 samples reported assay values over 0.2% V2O5, with a high value of 0.63%. Iron (Fe): 34 samples yielded assay values over 20% Fe, with a peak of 46.7%.

Saga Metals Corp. (‘ TSXV: SAGA ‘) (‘ FSE: 20H’ ) (‘ SAGA ‘ or the ‘ Company ‘), a North American exploration company focused on discovering critical minerals, is pleased to release assay results from its 2024 summer field program at the Radar Titanium-Vanadium (Ti-V) project in Labrador. The project, covering 17,250 hectares, is located approximately 10 km south of Cartwright and is road accessible, with early indications pointing to the potential for a classic layered mafic intrusive ore body.

The 2024 Radar Ti-V exploration program focused on expanding prospecting, geological mapping, and soil sampling in areas near previously identified geophysical anomalies. These efforts have produced encouraging results that reinforce Radar’s potential for hosting significant titanium and vanadium mineralization.

Key Total Database Assay Highlights Include:

Titanium Dioxide (TiO2): 49 samples returned assay values exceeding 4.0%, with a peak value of 11.1%. Vanadium Pentoxide (V2O5): 36 samples exceeded 0.2%, with a high of 0.63%. Iron (Fe): 34 samples returned values over 20%, reaching a high of 46.7%.

These promising results underscore Radar’s potential as a critical mineral asset and support the company’s strategic focus on developing critical mineral assets in North America.

Radar Project and corresponding geophysics highlight multiple anomalies across the property

Over a 20-day period in July 2024, a team of two geologists and six field technicians conducted detailed mapping, prospecting, and soil sampling across several highly prospective zones.

Key Program Details:

Samples Collected: A total of 221 rock samples and 582 soil samples were collected (including standards, blanks, and duplicates) across the entire property.

Target Zones: Fieldwork focused on three zones hosting significant electromagnetic anomalies, now named:

Hawkeye Zone Trapper Zone Unnamed Transitional Zone (between Hawkeye and Trapper)

Rock samples with corresponding titanium oxide (TiO2) and vanadium oxide (V2O5) values throughout the anomalous zones

Field observations consistently identified Gabbro Norite host rock mineralized with magnetite, ranging from fine-grained disseminations to massive magnetite layers. Assay results have confirmed the magnetic anomalies within both the Hawkeye and Trapper zones are mineralized, establishing a combined 8km strike length between the two zones. Preliminary indications suggest a possible connection between the trends through a transitional zone, which increases the mineralized strike to 9.5km through verified samples.

After two years of exploration at Radar, Saga Metals now has a comprehensive database of 388 rock samples. Assay results have yielded the following key values in the table below:

Summary of 2023 & 2024 assay results with 2% Ti cut-off grade in green and increasing to highest values in red

Hawkeye Zone Yields Strong Titanium and Vanadium Anomalies in Soil and Rock Samples:

Soil sampling in the Hawkeye Zone revealed significant anomalies for titanium (Ti) and vanadium (V) , with values ranging from 1.0 – 2.4% Ti and 200 – 445 ppm V . These soil anomalies closely correlate with rock sample assays, further validating the mineralization potential of the zone.

Rock samples collected from the Hawkeye Zone consistently returned values between 2.5 – 11.1% TiO2 and 0.2 – 0.66% V2O5 , confirming the presence of high-grade titanium and vanadium despite limited surface exposure. Several outcrops were successfully stripped throughout the zone, enabling better access for sampling and future exploration work.

These results underscore the potential of the Hawkeye Zone as a key target for further exploration.

Ti% in soil samples combined with TiO2% taken in rock samples over the main exposure of the Hawkeye Zone.

V ppm in soil samples combined with V2O5% taken in rock samples over the main exposure of the Hawkeye zone

Ti vs V scatter plot for the Hawkeye zone

Trapper Zone Shows Promising Titanium and Vanadium Anomalies Despite Limited Exposure:

The Trapper Zone spans a strike length of 4.3km , slightly longer than the Hawkeye Zone, though it has significantly less surface exposure. The lack of outcrop and subcrop initially posed challenges for the exploration team; however, the implementation of an extensive soil grid successfully yielded the first geochemical confirmation of the Trapper Zone’s correlation with previously identified geophysical anomalies.

Key findings from the Trapper Zone include:

Soil anomalies with values ranging from 1.0 – 1.1% Ti and 140 – 190 ppm V . Rock sample anomalies with values between 2.5 – 8% TiO2 and up to 0.28% V2O5 .

Although only 30 rock samples were collected due to limited exposure and ground cover, the consistent anomalies found in both soil and rock samples provide compelling evidence to justify targeted exploration in this zone.

Further work, including additional surface sampling, trenching, and geophysical surveys, is planned to unlock the full potential of the Trapper Zone.

Ti in soils and TiO2% in rock samples over the magnetic anomalies of the Trapper zone showing the parallel trend and proof of concept of the area

V ppm in soils and V2O5% in rock samples over the magnetic anomalies of the Trapper zone showing the parallel trend and proof of concept of the area

Ti vs V scatter plot for the Trapper zone

Transition Zone Presents Key Opportunity for Further Understanding of Radar Ti-V System:

A possible third, transitional zone, located between the Hawkeye and Trapper zones, presents a significant opportunity for further exploration. While its relationship to either zone remains unclear, this transitional area could help determine whether the Hawkeye and Trapper zones are folded limbs of the same system or represent different phases of a multi-phase, complex layered mafic intrusion.

One of the primary objectives of newly appointed Dr. Al Miller (see news release dated Oct 1, 2024 here ) will be to analyze the silicate content and relationships across these zones to uncover differences in their mineral phases. This work will be critical in understanding the genesis and structure of the system. Preliminary scatter plots of assay results confirm that titanium (Ti) and vanadium (V) are consistently locked within magnetite. Dr. Miller will explore how these elements behave across different stratigraphic levels and sample locations.

This research will deepen the company’s understanding of the project’s geology and inform future exploration strategies.

Ti vs V scatter plot for the Centre zone

Michael Garagan, CGO & Director of Saga Metals Corp., states, ‘the biggest success of this past season was our proof of concept that Ti and V mineralization exists over a large area of the property. Thanks to geophysical data from Cameron Martin, we were able to test the parallel Trapper zone and prove localized mineralization. The team is preparing detailed geophysics over the Hawkeye zone this fall to delineate drill targets in a future program. I’m truly excited that in only two short field seasons we have moved the Radar project to drill ready status confirming priority zones for a maiden program in 2025.’

Comparable Projects in the Grenville Geological Province:

A Map of the Grenville Geological Province

The Grenville Geological Province is known for its significant deposits of iron, titanium, vanadium (Fe-Ti-V), and Platinum Group Metals (PGM). A key comparison point is North America’s largest titanium-vanadium project, located at Lac Tio in Quebec, just southwest of Saga’s Radar Project. Notably, both projects share the same rich geological setting.

Strategic Resources is a Montreal-based development company focused on vanadium, high-purity iron ore and titanium with their BlackRock project located in Quebec west of Lac Tio right on the Grenville Front (as seen in the map above).

Like, the Radar Ti-V project, these projects all have basement rock dated over 1 billion years old, and all share components of the deep-rooted mafic rock of the Grenville Province.

Strategic Resources completed an amended feasibility study 1 on March 26, 2024, on the Southwest deposit hosted within the BlackRock project confirming a proven and probably reserve of 127.8Mt with 0.46% V2O5, 40.2% Fe2O3 and 7.8% TiO2. The Southwest deposit spans 2.5km in length and averaging 110m in mineralized thickness with a projected mine life of 39 years. The projected financial outcome of the mine estimates after-tax cashflows of C$12.055 billion with a 5.4-year payback period including an after-tax net-present-value (8%) of C$1.932 billion and an 18.2% after-tax internal rate of return.

About Saga Metals Corp.

Saga Metals Corp. is a North American mining company focused on the exploration and discovery of critical minerals that support the global transition to green energy. The company’s flagship asset, the Double Mer Uranium Project, is located in Labrador, Canada, covering 25,600 hectares. This project features uranium radiometrics that highlight an 18-kilometer east-west trend, with a confirmed 14-kilometer section producing samples as high as 4,281ppm U 3 O 8 and spectrometer readings of 22,000cps.

In addition to its uranium focus, SAGA owns the Legacy Lithium Property in Quebec’s Eeyou Istchee James Bay region. This project, developed in partnership with Rio Tinto, has been expanded through the acquisition of the Amirault Lithium Project. Together, these properties cover 65,849 hectares and share significant geological continuity with other major players in the area, including Rio Tinto, Winsome Resources, Azimut Exploration, and Loyal Lithium.

SAGA also holds secondary exploration assets in Labrador, where the company is focused on the discovery of titanium, vanadium, and iron ore. With a portfolio that spans key minerals crucial to the green energy transition, SAGA is strategically positioned to play an essential role in the clean energy future.

For more information, contact:
Saga Metals Corp.
Investor Relations
Tel: +1 (778) 930-1321
Email: info@sagametals.com
www.sagametals.com

Qualified Persons

Peter Webster, P. Geo., of Mercator Geological Services Limited are each a ‘qualified person’ as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects (‘ NI 43-101 ‘) and have reviewed and approved the scientific and technical content of this news release regarding the Radar Property.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or adequacy of this release. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Disclaimer

This news release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts. Forward-looking statements are often identified by terms such as ‘will’, ‘may’, ‘should’, ‘anticipates’, ‘expects’, ‘believes’, and similar expressions or the negative of these words or other comparable terminology. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. In particular, this news release contains forward-looking information pertaining to plans with respect to samples from its mineral exploration properties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include, but are not limited to, changes in the state of equity and debt markets, fluctuations in commodity prices, delays in obtaining required regulatory or governmental approvals, environmental risks, limitations on insurance coverage, failure to satisfy closing conditions in respect of the Offering, risks and uncertainties involved in the mineral exploration and development industry, and the risks detailed in the Prospectus and available under the Company’s profile at www.sedarplus.ca, and in the continuous disclosure filings made by the Company with securities regulations from time to time. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by applicable law.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9662f4b7-cfae-4a80-af0f-2c5b1ec55d2a  
  https://www.globenewswire.com/NewsRoom/AttachmentNg/033e0531-9aa3-4794-8993-9f9420a1bce6  
  https://www.globenewswire.com/NewsRoom/AttachmentNg/a8354168-e622-4003-a457-91a34804bdc6  
  https://www.globenewswire.com/NewsRoom/AttachmentNg/6ef0a651-907f-48a1-b2c4-1e22b4245498  
  https://www.globenewswire.com/NewsRoom/AttachmentNg/66b7783f-8e34-4444-9771-a983f77aa9e0  
  https://www.globenewswire.com/NewsRoom/AttachmentNg/7ea24dbc-62a4-4294-98f6-b2ac577398bc  
  https://www.globenewswire.com/NewsRoom/AttachmentNg/b7c09d5e-505d-46d0-892a-2f20b1dd055d  
  https://www.globenewswire.com/NewsRoom/AttachmentNg/23ab5aef-fcd6-4a0e-8028-97be18743945  
  https://www.globenewswire.com/NewsRoom/AttachmentNg/413a1308-900a-4bb7-bd28-44b170bb3dac  
  https://www.globenewswire.com/NewsRoom/AttachmentNg/b05dd32d-7f97-48fc-a2be-a3c23ad6700d  
  https://www.globenewswire.com/NewsRoom/AttachmentNg/1a832a3d-7dcb-4be9-8afb-fef2674ca8d6

Quetzal Copper Corp. (TSXV: Q) (‘Quetzal’ or the ‘Company’) is pleased to announce the results from the Annual General Meeting (the ‘Meeting’) held on October 16, 2024.

Shareholders voted in favour of all matters of business before the Meeting. Each of those matters is set out in detail in the Management Information Circular published in connection with the Meeting, which is available on the Company’s website https://quetzalcopper.com.

A total of 5,734,714 common shares were voted at the AGM represent 13.377% of the outstanding common shares of the Company. Shareholders voted in favour of (a) reappointing WDM Chartered Professional Accountants as auditors (98.943% in favour), (b) setting the number of directors at three (98.943% in favour), and (c) ratifying the and approving the Company’s stock option plan (98.856% in favour).

Election of Directors

The following nominees listed in the Management Information Circular were elected as directors of the Company until the next annual meeting of shareholders or until the successors are elected or appointed, with the voting results being as follows:

About Quetzal Copper

Quetzal is engaged in the acquisition, exploration, and development of mineral properties in British Columbia and Mexico. The Company’s principal project, Princeton Copper, is located adjacent to Hudbay’s Copper Mountain mine in southern British Columbia. The company currently has a portfolio of three properties located in British Columbia, Canada and one in Mexico.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS

The information contained herein contains ‘forward-looking statements’ within the meaning of the United States Private Securities Litigation Reform Act of 1995 and ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. ‘Forward-looking information’ includes, but is not limited to, statements with respect to the activities, events, or developments that the Company expects or anticipates will or may occur in the future, including, without limitation, planned exploration activities. Generally, but not always, forward-looking information and statements can be identified by the use of words such as ‘plans’, ‘expects’, ‘is expected’, ‘budget’, ‘scheduled’, ‘estimates’, ‘forecasts’, ‘intends’, ‘anticipates’, or ‘believes’ or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results ‘may’, ‘could’, ‘would’, ‘might’ or ‘will be taken’, ‘occur’ or ‘be achieved’ or the negative connotation thereof. Forward-looking statements in this news release include, among others, statements relating to exploration and development of the Company’s properties.

Such forward-looking information and statements are based on numerous assumptions, including among others, that the results of planned exploration activities are as anticipated, the anticipated cost of planned exploration activities, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms, that third party contractors, equipment and supplies and governmental and other approvals required to conduct the Company’s planned exploration activities will be available on reasonable terms and in a timely manner. Although the assumptions made by the Company in providing forward-looking information or making forward-looking statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate.

Forward-looking information and statements also involve known and unknown risks and uncertainties and other factors, which may cause actual events or results in future periods to differ materially from any projections of future events or results expressed or implied by such forward-looking information or statements, including, among others: negative operating cash flow and dependence on third party financing, uncertainty of additional financing, no known mineral reserves or resources, the limited operating history of the Company, aboriginal title and consultation issues, reliance on key management and other personnel, actual results of exploration activities being different than anticipated, changes in exploration programs based upon results, availability of third party contractors, availability of equipment and supplies, failure of equipment to operate as anticipated, accidents, effects of weather and other natural phenomena and other risks associated with the mineral exploration industry, environmental risks, changes in laws and regulations, community relations and delays in obtaining governmental or other approvals.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information or implied by forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227388

HIGHLIGHTS

Greater than 37ppb gold footprint over a 3.5 kilometre open trend with peak value of 1.3 grams gold.

The ‘Sienso’ gold footprint is next door to the BBM discovery – only 4km away.

Was revealed by the same Termite Mound sampling methodology used at BBM.

The ‘Sienso’ trend remains open to the south.

‘Sienso’ is situated within 100% Awalé owned property.

Vancouver, British Columbia–(Newsfile Corp. – October 22, 2024) – Awalé Resources Limited. (TSXV: ARIC) (‘Awalé’ or the ‘Company’) is pleased to announce it has uncovered a new and open 3.5 kilometre (‘km’) long > 37 parts per billion (‘ppb’) gold in termitaria footprint with a peak value of 1.3 grams per tonne (‘g/t’) gold (‘Au’). The program was completed within Awalé’s 100%-owned ‘Sienso’ permit next door to the BBM discovery which lies 4km along strike to the northwest (see Figures 1 and 2).

‘This new find at Sienso was made using the same termite mound sampling method that led to the BBM discovery. Termite mounds are great exploration tools as they provide in-situ sample from deep in the ground to be analysed for gold and other metals. This methodology has proven effective in our terrain, and we are delighted termitaria sampling has uncovered another large gold footprint at such an early stage of exploration on our 100%-owned ground. The discovery hole at BBM was drilled under a 1.2 g/t termitaria sample, so we are excited to follow-up this new target given its proximity and similar characteristics to BBM. With the seasonal rains soon subsiding, we will proceed with an Induced Polarization (‘IP’) geophysics program over this anomaly. If the geophysical results support the anomaly we will drill this target at the earliest opportunity.’- Commented Andrew Chubb, CEO of Awalé Resources.

Awalé completed a soil and termitaria survey in 2 phases: initially at a 400m x 50m spacing, followed by infill to a 200m x 50m spacing. All samples were analysed with a portable X-Ray Fluorescence (pXRF) machine and samples were selected for gold analysis after mapping the anomalous pathfinder elements. Higher tenor anomalism within the 3.5km trend is coincident with a bend in the structural trend, similar to the BBM discovery. Additionally, there are coincident late intrusive rocks spatially associated with the change in strike that also show similarities to the BBM discovery.

LINK TO VIDEO DISCUSSION

LINK TO HI RES IMAGES

Figure 1: Awalé Permits in NW Côte d’Ivoire – Showing new geochemistry area as red box in Awalé’s 100%-owned Sienso permit.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10016/227361_1e463f5b945a2829_002full.jpg

Figure 2: New 3.5km long > 37 ppb Gold footprint in Awalé’s 100%-owned Sienso Permit. A direct extension of the BBM disvovery.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10016/227361_1e463f5b945a2829_003full.jpg

100%-Owned Awalé

Sienso’s gold footprint is part of Awalé Resources’ 100%-owned ground. The Company’s Odienné Project consists of five (5) permits spanning 1,693 km2, all 100% Awalé owned – comprising the permits shown in orange in Figure 1. The Awalé-Newmont Joint Venture (‘OJV’) consists of two additional permits contiguous within the Odienné Project and cover a total area of 796 km2 (hatched permits in Figure 1). Awalé manages all exploration activities at OJV, with funding provided by Newmont Joint Ventures Limited (‘Newmont’) (see May 31, 2022 news release).

Awalé has discovered four gold, gold-copper, and gold-copper-silver-molybdenum discoveries within the OJV and has recently commenced exploration on its 100%-owned properties following an $11.5 million capital raise in April 2024.

The Odienné Project is underexplored and has multiple pipeline prospects with similar geochemical signatures to Iron Oxide Copper Gold (IOCG) and intrusive-related mineral systems with substantial upside potential. The Company benefits from a skilled and well seasoned technical team that allows it to continue exploring in a pro-mining jurisdiction that offers significant potential for district-scale discoveries.

Next Steps for the Sienso Permit

In this quarter, the Company will conduct IP geophysics over the new target area. If the results from the program align with the geochemical anomaly, an initial drill program will follow in Q1 2025. Surface Termitaria and Soil geochemistry will continue along the open southern extensions of the anomalies mentioned in this release as well as new programs along parralel structural targets further east within the Sienso permit area.

About Awalé Resources

Awalé is a diligent and systematic mineral exploration company focused on discovering large high-grade gold and copper-gold deposits. Exploration activities are currently undertaken in the underexplored regions of Côte d’Ivoire, where the Company is focused on the Odienné Copper-Gold Project spanning 2,489 km2 in seven permits.

Quality Control and Assurance

pXRF analysis is completed by the company with an Innov-X Vanta Handheld XRF Analyser, samples are hand crushed and dried where necessary and sieved to -80 mesh (passing 170 micron) and analysed for 90 seconds using 3beam ‘soil mode’. Standards are used in the stream every 50 analyses; field duplicates are also routinely analysed. Selected samples are sent to the laboratory where analytical work for soil and termitaria geochemical samples is being carried out at the independent Intertek Laboratories Australia Ltd. an ISO 17025 (2017) Certified Laboratory. Samples are stored at the Company’s field camps and put into sealed bags until collected by Intertek from the Company’s secure Odienné office and transported by Intertek to their laboratory in Tarkwa. Samples are logged in the tracking system, weighed, dried, and pulverized to better than 85%, passing a 75-micron screen. Samples were fire assayed with an AAS finish. Blanks, duplicates, and certified reference material (standards) are being used to monitor laboratory performance during the analysis.

Abbreviations Used in this Release

Qualified Person

The technical and scientific information contained in this news release has been reviewed and approved for release by Andrew Chubb, the Company’s Qualified Person as defined by National Instrument 43-101. Mr Chubb is the Company’s Chief Executive Officer and holds an Economic Geology degree, is a Member of the Australian Institute of Geoscientists (AIG) and is a Member of the Society of Economic Geologists (SEG). Mr. Chubb has over 20 years of experience in international mineral exploration and mining project evaluation.

AWALÉ Resources Limited
On behalf of the Board of Directors

‘Andrew Chubb’
Chief Executive Officer

FOR FURTHER INFORMATION, PLEASE CONTACT:
Andrew Chubb, CEO
(+356) 99139117
a.chubb@awaleresources.com

Ardem Keshishian, VP Corporate Development & Investor Relations
+1 (416) 471-5463
a.keshishian@awaleresources.com

The Company’s public documents may be accessed at www.sedarplus.com. For further information on the Company, please visit our website at www.awaleresources.com.

Forward-Looking Information

This press release contains forward-looking information within the meaning of Canadian securities laws (collectively ‘forward-looking statements’). Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, plans, postulate and similar expressions, or are those, which, by their nature, refer to future events. All statements that are not statements of historical fact are forward-looking statements. Forward-looking statements in this press release include but are not limited to statements regarding, the Company’s presence in Côte d’Ivoire and ability to achieve results, creation of value for Company shareholders, achievements under the Newmont JV, works on other properties, planned drilling, commencement of operations. Although the Company believes any forward-looking statements in this press release are reasonable, it can give no assurance that the expectations and assumptions in such statements will prove to be correct. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, changes in the state of equity and debt markets, fluctuations in commodity prices, delays in obtaining required regulatory or governmental approvals, and other risks involved in the mineral exploration and development industry, including those risks set out in the Company’s management’s discussion and analysis as filed under the Company’s profile at www.sedarplus.ca. Forward-looking information in this news release is based on the opinions and assumptions of management considered reasonable as of the date hereof, including that all necessary governmental and regulatory approvals will be received as and when expected. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information. The Company disclaims any intention or obligation to update or revise any forward-looking information, other than as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227361

MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company’s planned Phase III program.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced plans to expand the MAVERIC clinical development program and advance CardiolRx into a late-stage clinical trial (‘MAVERIC-2’) to evaluate the impact of CardiolRx in recurrent pericarditis patients following cessation of interleukin-1 (‘IL-1’) blocker therapy. MAVERIC-2 is expected to be initiated during Q4 at major pericardial disease centres in the United States and Europe and to report results ahead of the Company’s planned pivotal Phase III study in recurrent pericarditis.

‘MAVERIC-2 provides an exciting opportunity to expand the market potential for CardiolRx through the execution of a cost-effective study and potentially provides a path for an accelerated regulatory approval timeline,’ said David Elsley, President & CEO of Cardiol Therapeutics. ‘This important new study, designed in collaboration with an international panel of advisors comprised of experts in pericarditis, will also augment data from our planned Phase III MAVERIC-3 trial by exploring the potential for our lead oral drug candidate to assist the growing number of recurrent pericarditis patients who seek alternative options to chronic use of immunosuppressant biologics.’

MAVERIC-2 is a randomized, double-blind, placebo-controlled Phase II/III trial in approximately 110 patients. Patients with stable disease who are receiving IL-1 blocker treatment will be randomly assigned to receive either CardiolRx or placebo following cessation of the IL-1 blocker. The primary clinical objective of the trial will be to assess the impact of CardiolRx versus placebo on freedom from a new episode of recurrent pericarditis. Other clinical endpoints of interest include time to a new episode of pericarditis recurrence and change in patient-reported pericarditis chest pain score and the inflammatory marker C-reactive protein (‘CRP’).

IL-1 is a key pro-inflammatory cytokine in the pathophysiology of recurrent pericarditis. It is generated downstream following activation of the NLRP3 inflammasome and amplifies the autoinflammatory response characteristic of the disease. IL-1 blockers (rilonacept or anakinra) target and negate the activity of IL-1, but given their expense and immunosuppressant risks, they are generally prescribed as a third-line intervention in difficult-to-treat patients. There is a growing body of evidence indicating pericarditis recurrence rates are as high as seventy-five percent and onset is rapid following cessation of IL-1 blocker therapy. Currently, many patients who discontinue IL-1 blocker therapy and subsequently suffer a recurrence require rescue treatment with further administration of these biologics, potentially leading to IL-1 blocker dependence.

‘CardiolRx has been shown experimentally to inhibit assembly and activation of the NLRP3 inflammasome and the subsequent generation of IL-1, and following oral administration has led to marked reductions in pericarditis pain in patients suffering from chronic pericardial disease,’ said Dr. Andrew Hamer, Cardiol Therapeutics’ Chief Medical Officer and Head of Research & Development. ‘In addition to potentially offering a more accessible and non-immunosuppressive therapy to thousands of patients who are non-responsive or intolerant to current therapies, CardiolRx may also have therapeutic potential to prevent recurrences following discontinuation of IL-1 blockers, which would address an unmet need in a growing subset of patients dependant on long-term IL-1 blocker therapy.’

The Company previously announced positive topline data from MAvERIC-Pilot investigating CardiolRx for recurrent pericarditis which showed a substantial reduction in the primary efficacy endpoint of patient-reported pericarditis pain at the end of the 8-week treatment period (‘TP’), as well as normalization of inflammation – as measured by CRP – in 80% of the patients with elevated CRP at baseline. Eighty-nine percent of patients (24/27) progressed from the TP into the now completed extension period (‘EP’) of the study, defined as the additional 18-week period where background therapy was weaned and patients were followed on monotherapy of CardiolRx. Full clinical data will be reported in an oral presentation November 18th, 2024, at the American Heart Association Scientific Sessions 2024 and will include freedom from pericarditis recurrence during the 18-week EP, 26-week pericarditis pain score and inflammatory marker levels, and safety and tolerability outcomes. The totality of the MAvERIC-Pilot data will support and further inform the Company’s plans related to a second late-stage study called MAVERIC-3, a Phase III pivotal trial designed to assess CardiolRx for the treatment of the broader population of pericarditis patients to prevent recurrence.

Pericarditis

Pericarditis refers to inflammation of the pericardium (the membrane or sac that surrounds the heart) frequently resulting from a viral infection. Following that initial episode patients may have multiple recurrences, and the primary goal of treatment is recurrence prevention. Symptoms include debilitating chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Significant accumulation of pericardial fluid and scarring can progress to life-threatening constriction of the heart. The only FDA-approved therapy for recurrent pericarditis, launched in 2021, is costly and is primarily used as a third-line intervention. On an annual basis, the number of patients in the United States having experienced at least one recurrence is estimated at 38,000. Approximately 60% of patients with multiple recurrences (>1) still suffer for longer than two years, and one third are still impacted at five years. Hospitalization due to recurrent pericarditis is often associated with a 6-8-day length of stay and cost per stay is estimated to range between $20,000 and $30,000 in the United States.

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.

Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (‘US FDA’) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the Phase II MAvERIC-Pilot study (NCT05494788), the Phase II/III MAVERIC-2 trial, and the planned Phase III MAVERIC-3 trial. The ARCHER trial (NCT05180240) is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary Statement Regarding Forward-Looking Information:

This news release contains ‘forward-looking information’ within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are ‘forward-looking information’. Forward looking information contained herein may include, but is not limited to statements regarding the Company’s plans to expand the MAVERIC clinical development program and advance CardiolRx into a late-stage clinical trial called MAVERIC-2, the Company’s expectation to initiate the MAVERIC-2 study during the fourth quarter of 2024 at major pericardial disease centres in the United States and Europe and report results ahead of the Company’s planned pivotal Phase III study in recurrent pericarditis, the Company’s plans to conduct its Phase III study in recurrent pericarditis concurrently with MAVERIC-2, the Company’s intention to report full clinical data from the MAvERIC-Pilot study in an oral presentation at the American Heart Association Scientific Sessions 2024, the Company’s expectation that the full clinical data from the MAvERIC-Pilot study presented will include freedom from pericarditis recurrence during the 18-week EP, 26-week pericarditis pain score and inflammatory marker levels and safety and tolerability outcomes, the Company’s belief that the MAvERIC-Pilot study data will support and further inform the Company’s plans related to a second late-stage study called MAVERIC-3 which the Company intends to be a Phase III pivotal trial designed to assess CardiolRx for the treatment of the broader population of pericarditis patients to prevent recurrence, the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the molecular targets and mechanism of action of the Company’s product candidates, the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx, and the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission and Canadian securities regulators on April 1, 2024, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Supplement, the accompanying Base Prospectus and the documents incorporated by reference therein.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227396

Group Eleven Resources Corp. (TSXV: ZNG) (OTCBB: GRLVF) (FSE: 3GE) (‘Group Eleven’ or the ‘Company’) is pleased to announce results from a recent step-out hole of the 2024 drill program at the Company’s 100%-owned Ballywire zinc-lead-silver discovery (‘Ballywire’), PG West Project (‘PG West’), Republic of Ireland.

Highlights:

G11-3552-18 (a 50m step-out to the NNW from G11-3552-16) intersected:36.6m of 6.4% Zn+Pb (4.8% Zn and 1.6% Pb) and 26 g/t Ag (starting from 226.9m downhole) including:11.8m of 11.6% Zn+Pb (8.0% Zn and 3.5% Pb) and 48 g/t Ag, including:4.0m of 19.8% Zn+Pb (11.4% Zn and 8.4% Pb) and 104 g/t AgProvides additional evidence that mineralizing system at Ballywire is gaining strength to northeast with the emergence of a relatively flat-lying zone of zinc-rich massive sulphide lenses located at the base of the Waulsortian Limestone and extending at least 360m along strike (open)Zone is pierced by today’s intercept, as well as the following three previously released holes:G11-3552-12: 29.6m of 10.6% Zn+Pb and 78 g/t Ag (Group Eleven’s best intercept to date; released 11-Jun-2024)G11-3552-13: 6.1m of 11.4% Zn+Pb and 85 g/t Ag (released 01-Aug-24) andG11-3552-17: several massive sulphide zones including 4.9m of 9.7% Zn+Pb and 39 g/t Ag; and 4.2m of 15% Zn+Pb and 34 g/t Ag (released 24-Sep-2024)Above mineralization is contained within a 2.6km long northeasterly trend of significantly mineralized drill intercepts, and within an overall 6km long prospective trend, also northeasterly, defined by four gravity-high anomalies along the Waulsortian LimestoneTwo-rig drill program at Ballywire continues on schedule with the next assay results expected over the coming few weeks

‘Our recent drilling at Ballywire has intersected continuous, flat-lying, zinc-rich massive sulphide lenses at the base of the Waulsortian limestone, an important development that further aligns the project with classic Irish-type zinc deposits,’ stated Bart Jaworski, CEO. ‘We have hit these massive sulphides over an open 360 metres of strike and mineralization appears to be widening, intensifying and getting shallower as we move northeast.’

‘Our immediate priority is to further delineate this new, flat-lying, massive sulphide zone, while we also aim to grow the broader 2.6km footprint of the discovery and follow up on silver and copper potential beneath the zinc and lead rich horizons. Our drill program continues with two rigs and further drill results will be released over the coming weeks as we continue to explore Ballywire’s 6km long prospective trend.’

Exhibit 1. Cross-Section A-A’ of G11-3552-18 (50m Step-Out NNW) at Ballywire

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5685/227382_227382_d123fe80b4faaa32_002full.jpg

Note: G11-3552-20 and -22 is completed with assay pending; 50m step-out refers to the distance from G11-3552-16

Exhibit 2. Plan Map Showing New Drilling (G11-3552-18) at Ballywire

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5685/227382_227382_d123fe80b4faaa32_003full.jpg

Recent Hole from 2024 Drill Campaign at Ballywire Discovery

The Ballywire prospect at the Company’s 100%-owned PG West Project in Republic of Ireland, is a new zinc-lead-silver discovery (first announced Sept-2022). In addition to 36 holes drilled and reported by Group Eleven to date, the most recent step-out hole (G11-3552-18) of the 2024 program is reported today (see Exhibits 1 to 6).

Exhibit 3. Summary of Assays from G11-3552-18 at Ballywire

Note: True width of the overall mineralized package above is estimated at approx. 90-100% of the intersected interval

High-grade mineralization from G11-3552-18 consists predominantly of massive and semi-massive sulphide (sphalerite, galena, pyrite, chalcopyrite and suspected tennantite-tetrahedrite), as well as, disseminated and vein hosted sulphide mineralization. Mineralization occurs along and/or close to the base of the Waulsortian Limestone (see Exhibit 1).

Overall, recent drilling suggests the emergence of two distinct styles of mineralization. First, relatively flat-lying zinc-rich massive sulphide lenses and second, ‘other mineralization’, predominantly observed over the last two years and dominated by variably dipping massive sulphides, as well as, vein-hosted and disseminated mineralization (see Exhibit 2). Both styles occur at or near the base of the Waulsortian Limestone and offer great exploration opportunities as drilling progresses.

Exhibit 4. Emerging Massive Sulphide Zone and Upcoming Drill Results at Ballywire

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5685/227382_227382_d123fe80b4faaa32_004full.jpg

Looking forward, five drill holes (G11-3552-19 to -23; see Exhibit 4) have recently been completed with assay results expected over the coming weeks. Additionally, two other holes (-24 and -25) are in-progress, located northeast of G11-3552-18 and northeast of G11-3552-19, respectively. Exhibit 4 shows drilling to date across 1.25km of the overall 2.6km long trend (see Exhibit 2) of significantly mineralized drill intercepts (open in all directions).

Exhibit 5. Regional Gravity Map of Ballywire Area Showing 6km Long Prospective Trend

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5685/227382_227382_d123fe80b4faaa32_005full.jpg

Notes to Exhibit 6: (a) Pallas Green MRE is owned by Glencore (see Glencore’s Resources and Reserves Report dated December 31, 2023); (b) Stonepark MRE: see the ‘NI 43-101 Independent Report on the Zinc-Lead Exploration Project at Stonepark, County Limerick, Ireland’, by Gordon, Kelly and van Lente, with an effective date of April 26, 2018, as found on SEDAR; and (c) the historic estimate at Denison was reported by Westland Exploration Limited in ‘Report on Prospecting Licence 464’ by Dermot Hughes dated May, 1988; the historic estimate at Gortdrum was reported in ‘The Geology and Genesis of the Gortdrum Cu-Ag-Hg Orebody’ by G.M. Steed dated 1986; and the historic estimate at Tullacondra was first reported by Munster Base Metals Ltd in ‘Report on Mallow Property’ by David Wilbur, dated December 1973; and later summarized in ‘Cu-Ag Mineralization at Tullacondra, Mallow, Co. Cork’ by Wilbur and Carter in 1986; the above three historic estimates have not been verified as current mineral resources; none of the key assumptions, parameters and methods used to prepare the historic estimates were reported and no resource categories were used; significant data compilation, re-drilling and data verification may be required by a Qualified Person before the historic estimates can be verified and upgraded to be compliant with current NI 43-101 standards; a Qualified Person has not done sufficient work to classify them as a current mineral resource and the Company is not treating the historic estimates as current mineral resources. ‘Rathdowney Trend’ is the south-westerly projection of the Rathdowney Trend, hosting the historic Lisheen and Galmoy mines.

Exhibit 6. Regional Map of PG West (100% Interest) and Stonepark (76.56% Interest)

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5685/227382_227382_d123fe80b4faaa32_006full.jpg

Third Party Agreement

Qualified Person

Technical information in this news release has been approved by Professor Garth Earls, Eur Geol, P.Geo, FSEG, geological consultant at IGS (International Geoscience Services) Limited, and independent ‘Qualified Person’ as defined under Canadian National Instrument 43-101.

Quality Assurance/Quality Control (QA/QC) Information

Group Eleven inserts certified reference materials (‘CRMs’ or ‘Standards’) as well as blank material, to its sample stream as part of its industry-standard QA/QC programme. The QC results have been reviewed by the Qualified Person, who is satisfied that all the results are within acceptable parameters. The Qualified Person has validated the sampling and chain of custody protocols used by Group Eleven.

About Group Eleven Resources

Group Eleven Resources Corp. (TSX.V: ZNG; OTCBB: GRLVF and FRA: 3GE) is a mineral exploration company focused on advanced stage zinc exploration in the Republic of Ireland. Group Eleven announced the Ballywire discovery in September 2022. Key intercepts to date include:

10.8m of 10.0% Zn+Pb and 109 g/t Ag (G11-468-03)10.1m of 8.6% Zn+Pb and 46 g/t Ag (G11-468-06)10.5m of 14.7% Zn+Pb, 399 g/t Ag and 0.31% Cu (G11-468-12)11.2m of 8.9% Zn+Pb and 83 g/t Ag (G11-3552-03) 29.6m of 10.6% Zn+Pb, 78 g/t Ag and 0.15% Cu (G11-3552-12) and6.1m of 11.4% Zn+Pb, 85 g/t Ag (G11-3552-13)5.6m of 13.1% Zn+Pb, 116 g/t Ag (G11-3552-17)11.8m of 11.6% Zn+Pb, 48 g/t Ag (G11-3552-18)

The Company’s two largest shareholders are Glencore Canada Corp. (17.6% interest) and Michael Gentile (17.0%). Additional information about the Company is available at www.groupelevenresources.com.

ON BEHALF OF THE BOARD OF DIRECTORS
Bart Jaworski, P.Geo.
Chief Executive Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of applicable securities legislation. Such statements include, without limitation, statements regarding the future results of operations, performance and achievements of the Company, including the timing, content, cost and results of proposed work programs, the discovery and delineation of mineral deposits/resources/ reserves and geological interpretations. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking statements as a result of various factors, including, but not limited to, variations in the nature, quality and quantity of any mineral deposits that may be located. All of the Company’s public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review these materials, including the technical reports filed with respect to the Company’s mineral properties.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227382